Zelandopam free base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 328084

CAS#: 139233-53-7

Description: Zelandopam, also known as MYD-37; YM-435, is a dopamine D1 agonist potentially for the treatment of heart failure and hypertension. YM435 is a potent stimulant of pancreatic exocrine secretion by acting on DA D1 receptors of the pancreas in dogs. Intravenous administration of YM435 produces renal vasodilating and diuretic/natriuretic effects by stimulation of dopamine D1 receptors, and demonstrate that YM435 can inhibit angiotensin II-, renal nerve stimulation- and PAF-induced renal dysfunction.

Chemical Structure

img
Zelandopam free base
CAS# 139233-53-7
Instruction

Theoretical Analysis

MedKoo Cat#: 328084
Name: Zelandopam free base
CAS#: 139233-53-7
Chemical Formula: C15H15NO4
Exact Mass: 273.10
Molecular Weight: 273.288
Elemental Analysis: C, 65.92; H, 5.53; N, 5.13; O, 23.42

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Zelandopam; MYD-37; YM-435; MYD37; YM435.

IUPAC/Chemical Name: (S)-4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline-7,8-diol

InChi Key: FULLEMQICAKPOE-JTQLQIEISA-N

InChi Code: InChI=1S/C15H15NO4/c17-12-3-1-8(5-14(12)19)10-6-16-7-11-9(10)2-4-13(18)15(11)20/h1-5,10,16-20H,6-7H2/t10-/m0/s1

SMILES Code: OC1=C(O)C2=C(C=C1)[C@H](C3=CC=C(O)C(O)=C3)CNC2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 273.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Yatsu T, Aoki M, Tanaka A. Effect of zelandopam, a dopamine D1-like receptor agonist, in puromycin aminonucleoside nephrosis rats. Eur J Pharmacol. 2005 Mar 7;510(1-2):121-6. PubMed PMID: 15740732.

2: Yatsu T, Aoki M, Inagaki O. Preventive effect of zelandopam, a dopamine D1 receptor agonist, on cisplatin-induced acute renal failure in rats. Eur J Pharmacol. 2003 Feb 14;461(2-3):191-5. PubMed PMID: 12586214.

3: Yasunari K, Kohno M, Kano H, Hanehira T, Minami M, Yoshikawa J. Anti-atherosclerotic action of vascular D1 receptors. Clin Exp Pharmacol Physiol Suppl. 1999 Apr;26:S36-40. Review. PubMed PMID: 10386252.

4: Yatsu T, Arai Y, Takizawa K, Kasai-Nakagawa C, Takanashi M, Uchida W, Inagaki O, Tanaka A, Takenaka T. Effect of YM435, a dopamine DA1 receptor agonist, in a canine model of ischemic acute renal failure. Gen Pharmacol. 1998 Nov;31(5):803-7. PubMed PMID: 9809482.

5: Yatsu T, Arai Y, Sudoh K, Shibasaki M, Uchida W, Inagaki O, Tanaka A, Takenaka T. Effect of YM435, a novel dopamine DA1 receptor agonist, in a canine model of acute congestive heart failure. Gen Pharmacol. 1998 May;30(5):733-7. PubMed PMID: 9559326.

6: Yasunari K, Kohno M, Hasuma T, Horio T, Kano H, Yokokawa K, Minami M, Yoshikawa J. Dopamine as a novel antimigration and antiproliferative factor of vascular smooth muscle cells through dopamine D1-like receptors. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):3164-73. PubMed PMID: 9409307.

7: Yatsu T, Miyamoto I, Kaneko-Takanuki F, Watanabe T, Takenaka T. Pharmacological and pharmacokinetic characteristics of YM435, a novel dopamine DA1-receptor agonist, in anaesthetized dogs. J Pharm Pharmacol. 1997 Sep;49(9):892-6. PubMed PMID: 9306257.

8: Yatsu T, Uchida W, Inagaki O, Tanaka A, Takenaka T. Dopamine DA1 receptor agonist activity of YM435 in the canine renal vasculature. Gen Pharmacol. 1997 Aug;29(2):229-32. PubMed PMID: 9251904.

9: Yatsu T, Arai Y, Takizawa K, Kasai-Nakagawa C, Takanashi M, Uchida W, Inagaki O, Tanaka A, Asano M, Honda K, Takenaka T. Renal effect of YM435, a new dopamine D1 receptor agonist, in anesthetized dogs. Eur J Pharmacol. 1997 Mar 12;322(1):45-53. PubMed PMID: 9088869.

10: Yatsu T, Takizawa K, Kasai-Nakagawa C, Uchida W, Tanaka A, Asano M, Honda K, Takenaka T. Hemodynamic characterization of YM435, a novel dopamine DA1 receptor agonist, in anesthetized dogs. J Cardiovasc Pharmacol. 1997 Mar;29(3):382-8. PubMed PMID: 9125677.

11: Yasunari K, Kohno M, Kano H, Yokokawa K, Minami M, Yoshikawa J. Dopamine D1-like receptor stimulation inhibits hypertrophy induced by platelet-derived growth factor in cultured rat renal vascular smooth muscle cells. Hypertension. 1997 Jan;29(1 Pt 2):350-5. PubMed PMID: 9039126.

12: Anan H, Tanaka A, Tsuzuki R, Yokota M, Yatsu T, Fujikura T. 4-(3,4-Dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline derivatives. II. Their renal vasodilation activity and structure-activity relationship. Chem Pharm Bull (Tokyo). 1996 Oct;44(10):1865-70. PubMed PMID: 8904813.

13: Iwatsuki K, Horiuchi A, Ren LM, Chiba S. D-1 dopamine receptors mediate dopamine-induced pancreatic exocrine secretion in anesthetized dogs. Hypertens Res. 1995 Jun;18 Suppl 1:S173-4. PubMed PMID: 8529053.

14: Ofori S, De Raad S, Bugnon O, Schorderet M. Effects of YM 435 and A 77636 on dopamine D-1 receptors in bovine retina in vitro. Gen Pharmacol. 1995 Jan;26(1):51-7. PubMed PMID: 7713366.

15: Takenaka T, Forster H, Epstein M. Characterization of the renal microvascular actions of a new dopaminergic (DA1) agonist, YM435. J Pharmacol Exp Ther. 1993 Mar;264(3):1154-9. PubMed PMID: 8095547.

16: Iwatsuki K, Ren LM, Chiba S. Effects of YM435, a novel dopamine D1 receptor agonist, on pancreatic exocrine secretion in anesthetized dogs. Eur J Pharmacol. 1992 Aug 6;218(2-3):237-41. PubMed PMID: 1425944.

17: Anan H, Tanaka A, Tsuzuki R, Yokota M, Yatsu T, Honda K, Asano M, Fujita S, Furuya T, Fujikura T. Synthesis, resolution, and renal vasodilation activity of novel DA1 agonists: 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline derivatives. Chem Pharm Bull (Tokyo). 1991 Nov;39(11):2910-4. PubMed PMID: 1839245.